The Europe Medical Drug‑releasing Micropump market was valued at USD 0.35 billion in 2025 and is projected to grow from USD 0·38 billion in 2026 to USD 0·64 billion by 2034, exhibiting a CAGR of 9·3% during the forecast period. A Medical Drug‑releasing Micropump is a miniature infusion device designed for precise, controlled, and continuous drug delivery. These systems...

According to a new report from Intel Market Research, the global diabetes drugs market was valued at USD 99,880 million in 2024 and is projected to grow from USD 108,000 million in 2025 to USD 218,800 million by 2032, exhibiting a robust CAGR of 12.1% during the forecast period (2025–2032). This growth is driven by the rising global prevalence of diabetes, increased healthcare...

According to a new report from Intel Market Research, the global Recombinant Human Insulin market was valued at USD 5.8 billion in 2025 and is projected to grow from USD 6.3 billion in 2026 to USD 9.7 billion by 2034, exhibiting a steady CAGR of 5.6% during the forecast period (2026–2034). This growth is driven by the rising prevalence of diabetes globally, advancements in...

  Diabetes has become one of the most common lifestyle diseases affecting millions of people worldwide. Effective management and early diagnosis are essential to prevent complications and maintain a healthy quality of life. Terna Specialty Hospital & Research Centre provide patients with comprehensive care, advanced diagnostic facilities, and personalized treatment plans designed to...

" According to the latest report published by Data Bridge Market Research, the Tubeless Insulin Pump Market The global tubeless insulin pump market size was valued at USD 3.04 billion in 2025and is expected to reach USD 17.12 billion by 2033, at a CAGR of 24.12% during the forecast period The large scale Tubeless Insulin Pump Market report comprises of...

According to a newly published market research report by 24LifeSciences, global ultra long acting insulin market was valued at USD 15.2 billion in 2025 and is projected to reach USD 24.8 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period 20262034. Ultra long acting insulin represents the most advanced form of basal insulin therapy, providing...